1
|
Park SW, Park S, Choi HK, Park HJ, Yu W, Kim HS, Jeon M, Chung SC, Ban K, Moon S, Bae YM. Blue laser-induced selective vasorelaxation by the activation of NOSs. Microvasc Res 2021; 136:104165. [PMID: 33845105 DOI: 10.1016/j.mvr.2021.104165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 03/29/2021] [Accepted: 03/29/2021] [Indexed: 10/21/2022]
Abstract
Phototherapy has been tried for treating cardiovascular diseases. In particular, ultraviolet and blue visible lights were suggested to be useful due to their nitric oxide (NO)-production ability in the skin. However, the effects of blue light on the arterial contractility are controversial. Here, we hypothesized that appropriate protocol of blue laser can induce selective vasorelaxation by activating vasodilating signaling molecules in arteries. Using organ chamber arterial mechanics, NO assay, Matrigel assay, and microarray, we showed that a 200-Hz, 300-μs, 445-nm pulsed-laser (total energy of 600 mJ; spot size 4 mm) induced selective vasorelaxation, without vasocontraction in rat mesenteric arteries. The laser stimulation increased NO production in the cord blood-endothelial progenitor cells (CB-EPCs). Both the laser-induced vasorelaxation and NO production were inhibited by a non-selective, pan-NO synthase inhibitor, L-NG-Nitro arginine methyl ester. Microarray study in CB-EPCs suggested up-regulation of cryptochrome (CRY)2 as well as NO synthase (NOS)1 and NOSTRIN (NOS trafficking) by the laser. In conclusion, this study suggests that the 445-nm blue puled-laser can induce vasorelaxation possibly via the CRY photoreceptors and NOSs activation. The blue laser-therapy would be useful for treating systemic hypertension as well as improving local blood flow depending on the area of irradiation.
Collapse
Affiliation(s)
- Sang Woong Park
- Medical Services, Eulji University, Seongnam, Gyeonggi-do 13135, South Korea
| | - Soonjung Park
- Department of Stem Cell Biology, School of Medicine, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, South Korea
| | - Hea Kyung Choi
- Medical Services, Eulji University, Seongnam, Gyeonggi-do 13135, South Korea
| | - Hyun Ji Park
- Department of Physiology, KU Open Innovation Center, Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, South Korea
| | - Wonjong Yu
- Department of Physical Therapy, Eulji University, 13135, South Korea
| | - Hyung-Sik Kim
- Department of Biomedical Engineering, BK21+ Research Institute of Biomedical Engineering, School of ICT Convergence Engineering, College of Science & Technology, Konkuk University Chungju, Chungbuk 380-701, South Korea
| | - Mina Jeon
- Department of Physiology, KU Open Innovation Center, Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, South Korea
| | - Soon-Cheol Chung
- Department of Biomedical Engineering, BK21+ Research Institute of Biomedical Engineering, School of ICT Convergence Engineering, College of Science & Technology, Konkuk University Chungju, Chungbuk 380-701, South Korea
| | - Kiwon Ban
- Department of Biomedical Sciences, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong Special Administrative Region
| | - Sunghwan Moon
- Department of Stem Cell Biology, School of Medicine, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, South Korea; Division of Stem Cell Research, T&R Biofab Co. Ltd, Seongnam-si 13494, Republic of Korea.
| | - Young Min Bae
- Department of Physiology, KU Open Innovation Center, Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, South Korea.
| |
Collapse
|